Clinical Trial Results:
Randomized, multicentric, partially double blind placebo-controlled phase II study for examining the influence of Ribavirin on the initial virological response in previous untreated patients with chronic Hepatitis C Virus Genotype 1 infection receiving treatment of Peginterferon alfa-2a (40KD) and Ribavirin with a six week pretreatment-phase of Ribavirin/placebo or PEG-Interferon monotherapy
Summary
|
|
EudraCT number |
2006-000935-86 |
Trial protocol |
DE |
Global completion date |
26 Apr 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
06 Aug 2016
|
First version publication date |
06 Aug 2016
|
Other versions |
|
Summary report(s) |
ML19301 Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.